Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
ABSTRACT Introduction Immune checkpoint inhibitors have made a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust predictive biomarkers for patient stratification are lacking. Here, we characterize early on-treatment proteomic changes in blood plasma to gain a better understanding of treatment response and resistance.Methods Pre-treatment (T0) and on-treatment (T1) plasma samples were collected from 225 NSCLC patients receiving PD-1/PD-L1 inhibitor-based regimens. Plasma was profiled using aptamer-based technology to quantify approximately 7000 plasma proteins per sample. Proteins displaying significant fold changes (T1:T0) were analyzed further to identify associations with clinical outcomes. Bioinformatic analyses of upregulated proteins were performed to determine potential cell origins and enriched biological processes.Results The levels of 142 proteins were significantly increased in the plasma of NSCLC patients following ICI-based treatments. Soluble PD-1 exhibited the highest increase, with a positive correlation to tumor PD-L1 status. Bioinformatic analysis of the ICI monotherapy dataset revealed a set of 30 upregulated proteins that formed a single, highly interconnected network with CD8A serving as a central hub, suggesting T cell activation during ICI treatment. Notably, the T cell-related network was detected regardless of clinical benefit. Lastly, circulating proteins of alveolar origin were identified as potential biomarkers of limited clinical benefit, possibly due to a link with cellular stress and lung damage.Conclusions Our study provides insights into the biological processes activated during ICI-based therapy, highlighting the potential of plasma proteomics to identify mechanisms of therapy resistance and potential biomarkers for outcome..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 06. Mai Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bar, Jair [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.01.02.573876 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042073480 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042073480 | ||
| 003 | DE-627 | ||
| 005 | 20240507095023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240106s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.01.02.573876 |2 doi | |
| 035 | |a (DE-627)XBI042073480 | ||
| 035 | |a (biorXiv)10.1101/2024.01.02.573876 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bar, Jair |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction Immune checkpoint inhibitors have made a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust predictive biomarkers for patient stratification are lacking. Here, we characterize early on-treatment proteomic changes in blood plasma to gain a better understanding of treatment response and resistance.Methods Pre-treatment (T0) and on-treatment (T1) plasma samples were collected from 225 NSCLC patients receiving PD-1/PD-L1 inhibitor-based regimens. Plasma was profiled using aptamer-based technology to quantify approximately 7000 plasma proteins per sample. Proteins displaying significant fold changes (T1:T0) were analyzed further to identify associations with clinical outcomes. Bioinformatic analyses of upregulated proteins were performed to determine potential cell origins and enriched biological processes.Results The levels of 142 proteins were significantly increased in the plasma of NSCLC patients following ICI-based treatments. Soluble PD-1 exhibited the highest increase, with a positive correlation to tumor PD-L1 status. Bioinformatic analysis of the ICI monotherapy dataset revealed a set of 30 upregulated proteins that formed a single, highly interconnected network with CD8A serving as a central hub, suggesting T cell activation during ICI treatment. Notably, the T cell-related network was detected regardless of clinical benefit. Lastly, circulating proteins of alveolar origin were identified as potential biomarkers of limited clinical benefit, possibly due to a link with cellular stress and lung damage.Conclusions Our study provides insights into the biological processes activated during ICI-based therapy, highlighting the potential of plasma proteomics to identify mechanisms of therapy resistance and potential biomarkers for outcome. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Leibowitz, Raya |e verfasserin |4 aut | |
| 700 | 1 | |a Reinmuth, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Ammendola, Astrid |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Eyal |e verfasserin |4 aut | |
| 700 | 1 | |a Moskovitz, Mor |e verfasserin |4 aut | |
| 700 | 1 | |a Levy-Barda, Adva |e verfasserin |4 aut | |
| 700 | 1 | |a Lotem, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Katzenelson, Rivka |e verfasserin |4 aut | |
| 700 | 1 | |a Agbarya, Abed |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-Amna, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Gottfried, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Harkovsky, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Ido |e verfasserin |4 aut | |
| 700 | 1 | |a Tepper, Ella |e verfasserin |4 aut | |
| 700 | 1 | |a Loewenthal, Gil |e verfasserin |4 aut | |
| 700 | 1 | |a Yellin, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Brody, Yehuda |e verfasserin |4 aut | |
| 700 | 1 | |a Dahan, Nili |e verfasserin |4 aut | |
| 700 | 1 | |a Yanko, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Lahav, Coren |e verfasserin |4 aut | |
| 700 | 1 | |a Harel, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Shoval, Shani Raveh |e verfasserin |4 aut | |
| 700 | 1 | |a Elon, Yehonatan |e verfasserin |4 aut | |
| 700 | 1 | |a Sela, Itamar |e verfasserin |4 aut | |
| 700 | 1 | |a Dicker, Adam P. |e verfasserin |4 aut | |
| 700 | 1 | |a Shaked, Yuval |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 06. Mai |
| 773 | 1 | 8 | |g year:2024 |g day:06 |g month:05 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2024.1364473 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.01.02.573876 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 06 |c 05 | ||